ServiziMenu principale

<< Torna a "Studi Fase I"

LCB-1801-001 - A Phase 1, Open-label, Dose Finding Study of NI-1801, a Bispecific Mesothelin x CD47 Engaging Antibody, in Patients With Mesothelin Expressing Solid Cancers

Studio Clinico

Patologia: Neoplasie della mammella, Neoplasie del polmone, Tumori dell’ovaio

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico

Randomizzato: No

Fase di studio: 1,

Linee di trattamento: Seconda linea, Terza/N linea

Criteri di inclusione: 

1. Adults ≥ 18 years of age at the time of signing the informed consent form.
2. Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer (high-grade serous or endometroid), triple-negative breast cancer, or non-squamous non-small cell lung cancer.
3. MSLN expression with staining intensity of ≥ 2+ as per IHC in ≥ 60 % of tumor cells.
4. Patients with advanced, metastatic, or recurrent disease
    - after at least 1 prior systemic treatment for the primary malignancy and
    - who have failed treatment with, are intolerant to, or are not candidates for available therapies that are known to confer a clinical benefit to patients with these tumor entities.
5. Measurable disease according to the revised RECIST guideline version 1.1
6. Eastern Cooperative Oncology Group performance status 0-1.
7. Adequate organ function
8. Adequate contraception
9. Life expectancy of at least 2 months.

Criteri di esclusione: 

1. Patient has known hypersensitivity to NI-1801 or any of the constituent compounds.
2. Radiotherapy to the target lesions within 4 weeks prior to the first NI-1801 infusion.
3. Prior anti-cancer therapy including chemotherapy, hormonal therapy, and investigational agents within 2 weeks or within ≤ 5 half-lives prior to starting NI-1801 dosing (up to a maximum of 4 weeks), whichever is longer.
4. Other investigational therapies must not be used, i.e., treatment within another clinical trial is not permitted, while the patient is on study.
5. Severe cardiac dysfunction (NYHA classification III-IV).
6. Significant hepatic dysfunction (serum bilirubin ≥ 1.5 mg/dL or AST and/or ALT ≥ 2.5 times normal level), unless related to liver metastasis.
7. Uncontrolled active systemic bacterial, viral, fungal, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks prior to first dose of NI-1801.
8. Patients with concomitant active malignancy, requiring ongoing systemic treatment.
9. Patients with known CNS metastases.
10. Platelet count < 100 x 10^9/L (transfusion support within 14 days before the test is not allowed).
11. Hemoglobin < 10.0 g/dL. Prior RBC transfusion is permitted.
12. ANC < 1 x 10^9/L (the use of colony stimulating factors, G-CSF or GM-CSF, within 14 days before the test is not allowed).
13. Pregnancy and lactation.
14. Significant medical diseases or conditions, including laboratory abnormalities, as assessed by the Investigators and Sponsor, that would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, and severely immunocompromised state, major surgery ≤ 4 weeks prior to starting NI-1801.
15. Prior treatment with a CD47, SIRPα, or MSLN targeting agent.
16. Patients in whom acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure have not resolved to Grade ≤ 1 or returned to baseline except for alopecia (any grade), anemia, and peripheral neuropathy (for the latter, recovery to Grade ≤ 2 is acceptable).

Trattamento sperimentale: 


Trattamento di controllo: 


Centri partecipanti

Nord Italia

Istituto Europeo di Oncologia
Via Ripamonti 435 - 20141 Milano - MI
Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative

Riferimento: Prof. Giuseppe Curigliano
Telefono: 0257489599


Istituto Clinico Humanitas Rozzano
Via Manzoni 56 - 20089 Rozzano - MI


AOUI Verona - Borgo Roma
Piazzale Ludovico Antonio Scuro 10 - 37134 Verona - VR
Centro Ricerche Cliniche di Verona, c/o Policlinico G.B. Rossi

Riferimento: Dr. Andrea Zivi
Telefono: 0458128120

Informazioni Generali


Numero di iscrizione a registro: 2021-003808-40 - NCT05403554

Data di inserimento: 07.03.2024


Light Chain Bioscience - Novimmune SA

Principal Investigator ITALIA

Istituto Europeo di Oncologia, Milano

Riferimento: Prof. Giuseppe Curigliano

Telefono: 0257489599


Localita: Milano


<< Torna a "Studi Fase I"